Monkeypox Treatment Market
Market Insights on Monkeypox Treatment covering sales outlook, demand forecast & up-to-date key trends
Monkeypox Treatment Market by Treatment Type, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Monkeypox Treatment Market Snapshot (2023 to 2033)
The global monkeypox treatment market is expected to reach a valuation of US$ 93.84 million in 2023 and is projected to grow to US$ 249 million by 2033, registering a CAGR of 10.25% during the forecast period. The demand for effective treatment, vaccination, and other rare disease therapeutics are anticipated to propel growth of the global monkeypox therapeutics market during the forecast period.
There is presently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and a rise in demand for pain and itch relief caused by boils and rashes are positively impacting growth of monkeypox treatment market. Moreover, surge in the products approvals is also projected to fuel monkeypox treatment market during the forecast period.
Likewise, according to the United states Food and Drug Administration, on 9 August 2022, Bavarian Nordic, a completely integrated vaccine company concentrated on the development, manufacturing and commercialization of life-saving vaccines, declared that its Jynneos vaccine received the approval from United states food and drugs administration as an emergency drug for treatment of growing monkeypox disease. This will help in expansion of market in the forecast period.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 93.84 million |
|
Anticipated Forecast Value (2033) |
US$ 249 million |
|
Projected Growth Rate (2023 to 2033) |
CAGR 10.25% |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Monkeypox Treatment Management Demand Analysis vs. Forecast 2023 to 2033
The market for Monkeypox treatment was worth US$ 64 million in 2018, while growing at a CAGR of 7.95 % during the historical period. Mounting demand of monkeypox treatment and increasing research for specific treatment for monkeypox led to vast opportunities which will aid in market expansion. Governments around the world are pro-actively investing in the research and development for the development of effective drug and vaccines to control the growing number of monkeypox cases.
On the other hand, various governments have started promoting genetic engineering for development of vaccines and also begun campaigns for spreading awareness about the potential disease cause and prevention. In addition, rise in healthcare expenditure day by day for advance in treatment of monkeypox disease will witness profitable growth prospects during the forecast period that will benefit the market in long-term.
For instance, In North America and various European countries, approval of two vaccines and antiviral drug for treatment of monkeypox, previously used for smallpox treatment and eradication will lead to market expansion in the projected period. The live attenuated vaccine, Imvanex (in Europe) Jynneos (in the USA) is developed by Bavarian Nordic. Likewise, smallpox shot ACAM2000 was developed by EMERGENT (Emergent BioSolutions). Considering the above-mentioned factors, product approvals and developments, the monkeypox treatment market is projected to reach US$ 249 million by 2033, with a CAGR of 10.25%.
Which are Some Prominent Drivers of the Monkeypox Treatment Market?
Surging demand for timely vaccines and potential disease treatments is expected to drive growth of monkeypox treatment market during the forecast period. Active investments in the research and development of effective vaccines and drugs to manage disease spread and treat affected patients is driving growth of this market. Additionally, the government is taking steps to facilitate drug development by utilizing genetic engineering tools in order to provide vaccination in the event that the virus evolves and impacts massive portion of the populace.
On the other hand, genomic sequencing for the virus would unravel the specific infection-causing sequences, which could help in the early diagnosis of viral infection and the development of effective vaccines for the population at risk of infection in the forthcoming period. Also, increasing healthcare expenditures by the population is fuelling investments for the development of new vaccines, which will drive global monkeypox treatment market during the projected period. Currently, tecovirimat is the treatment of choice for people in treating monkeypox. This is expected to propel growth during the forecast period.
Likewise, EMA’s human medicines committee recommended an extension of the indication of smallpox vaccine IMVANEX to protect people from monkeypox infection. IMVANEX was approved in 2013 but it has been considered a crucial vaccine because of the similarities between smallpox and monkeypox. Furthermore, increasing Research and development activities and use of smallpox vaccine as an off-label product for vaccination against monkeypox are anticipated to propel market in the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
Side-effects related to drug use to restrain market expansion
The growing side effects related to the drugs used to treat monkeypox, is anticipated to restrict growth of the market. Dearth of awareness and knowledge of the disease about the supportive treatment and slow approval rate of specific therapeutic treatment for monkeypox are the major factor expected to restrain growth of this market.
Region-Wise Insights
What is the growth outlook in North America?
North America expected to dominate market with maximum share
North America dominated the market with a revenue share of 40.5% in 2022. It is projected to possess around 48% market share by end of the forecast period while growing at a CAGR of 9.1%. Growth is attributed to presence of many dominating players, coupled with numerous strategic initiatives undertaken by them. Also, the rise in disease prevalence and growing awareness among people regarding vaccination are estimated to propel growth of regional market. Additionally, favorable support from the government and higher research and development investments are expected to provide lucrative opportunities for market growth of monkeypox treatment in this region.
In addition, on 4 august 2022, the United States department of health and human services, announced monkeypox outbreak as a public health emergency. Due to this, there is a surging demand for vaccines and better treatment for monkeypox. Also, rising prevalence of monkeypox disease and growing demand for vaccines and new treatment for monkeypox is projected to fuel growth of the monkeypox treatment market in this region.
Similarly, the United states government included the ACAM2000 drug in its strategic stockpile for the treatment of monkeypox. However, it is not commercially available yet. Presently, Siga Technologies’ Tecovirimat (TPOXX) and Chimerix’s brincidofovir (TEMBEXA) are only two FDA-approved drugs for smallpox that are generally recommended for the treatment of certain patients with monkeypox. These approvals will help in expansion of market in this region during the forecast period.
What is the growth prospect in Asia-Pacific?
Asia Pacific market expected to reflect fastest CAGR
Asia Pacific is projected to witness the fastest growth of 11% during the forecast period. The growing number of monkeypox infections and increasing research and development activities for developing prevention and therapeutic options are some of the primary factors fuelling market growth.
Rising prevalence of infection in Asia Pacific countries such as Singapore, Australia, and India are anticipated to propel market growth.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category wise Insights
By route of administration, which segment will possess significant share?
Oral segment to dominate market with maximum share
In 2022, the oral segment held the largest market share of 65.0% and it is estimated to possess more than 70% share by end of the forecast period. Surging demand for oral route therapeutics, ease of administration, and cost-effectiveness of oral products are some factors contributing to the segment expansion.
Likewise, most common drugs such as tecovirimat and brincidofovir are administered orally which are expected to boost growth of this segment during the forecast period.
By treatment type, which segment will possess market dominance?
Tecovirimat driving growth with maximum share
This segment is estimated to account for 61% market share in monkeypox treatment market by end of 2033. This drug is expected to grow with a CAGR of 11.2% during the forecast period. Growth is attributed to the accepted safety profile offered by Tecovirimat during the clinical trials and for the treatment of monkey pox in severe cases.
This drug is also accepted as first line of therapeutic treatment recommended by United states food and drug administration (FDA). It is also approved in European countries as well. The validation provided by these bodies and promising results from clinical trials are driving growth of this segment. Moreover, ‘Tecovirimat’ is proved to be only effective drug against human monkeypox virus in vitro at nanomolar concentrations. Thus, presenting opportunities for market expansion of this segment.
Start-ups in Monkeypox Treatment Market
Start-ups help in understanding the outlook of any market. Start-ups also have the potential to generate higher returns which directly benefits in expansion of any market. This is because these are typically more efficient at converting inputs into outputs. These are more flexible and adaptable, able to shift quickly in response to changing market conditions. Some of the start-ups that will aid in expansion of monkeypox treatment market are:
- Chimirax is a Durham, United Kingdom based start-up, founded in 2002. It is the developer of antiviral oral therapeutics. Its product pipeline involves Brincidofovir for smallpox, ONC201 for mutant glioma, DSTAT for acute myeloid leukemia, and ONC206 for solid tumors. It enhances quality of life for patients in multiple settings, including transplant, oncology, acute care, and global health. It was granted total funding of USD 95.2 million from Morningside Ventures, Pappas Ventures, and 6 more.
- Emergex is a United Kingdom-based start-up, founded in 2016. It is developing T-cell vaccines for treating viral and bacterial infections like monkeypox. The company also targets Zika, Ebola, pandemic flu, and antibiotic-resistant bacteria. The technology delivers immunogenic peptides which result in T-cell immune response. The dominant candidate of the company, EMX-001, which is a flavivirus vaccine. It is used to treat zika, dengue, and yellow fever. The candidate is in the preclinical stage. It received total funding of USD 30 million until February 2022.
Market Competition
The global Monkeypox treatment market is extremely competitive owing to presence of large number of players and innovative product offerings. Additionally, business expansion activities through partnerships and agreements are factors projected to further increase the competition. The major players in the market are: SIGA Technologies Inc., Chimerix, Inc, Bavarian Nordic, Sanofi SA, Emcure Pharmaceuticals, Jinan Jinda Pharmaceutical Chemistry Co., Ltd, Emergent Pharmaceuticals, Gilead Sciences, Inc., Hetero, Piramal Pharma Solutions
Some Recent Developments in the market are:
Key market players are concentrating on adoption of inorganic growth strategies such as acquisition, partnerships and collaboration in order to improve its product portfolio. This is anticipated to drive the global monkeypox treatment market.
- In 2021, SIGA, a commercial-stage pharmaceutical company concentrated on the health security market, declared that it entered into a collaboration with Oxford University in the UK to provide ‘tecovirimat’ to treat individuals suffered from monkeypox in the Central African Republic (CAR).
- In July 2022, Bavarian Nordic A/S declared that the company received an additional order for 2.5 million doses of JYNNEOS from the USA BARDA.
- In August 2022, the United states FDA authorised emergency use of JYNNEOS vaccine intradermal injectable for healthcare professionals over 18 years of age and older determined to be at higher risk of monkeypox infection.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 93.84 million |
|
Market Value in 2033 |
US$ 249 million |
|
Growth Rate |
CAGR of 10.25% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Monkeypox Treatment Industry Survey
By Treatment Type:
- Prophylactic- Vaccines
- Therapeutic
- Tecovirimat
- Brincidofovir
- Cidofovir
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Frequently Asked Questions
FMI projects the global Monkeypox treatment market to expand at a 10.25 % value CAGR by 2033.
The global Monkeypox treatment market is expected to garner a market value of US$ 249 million by 2033.
FMI has projected North America to be one of the most lucrative regions for Monkeypox treatment market.
Asia Pacific region is anticipated to grow fastest during the forecast period.
Table of Content
1. Executive Summary | Monkeypox Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Prophylactic – Vaccines
5.3.2. Therapeutic
5.3.2.1. Tecovirimat
5.3.2.2. Brincidofovir
5.3.2.3. Cidofovir
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Injectable
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Treatment Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom (UK)
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Treatment Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Treatment Type
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of Middle East and Africa
13.2.2. By Treatment Type
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Treatment Type
14.1.2.2. By Route of Administration
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Treatment Type
14.2.2.2. By Route of Administration
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Treatment Type
14.3.2.2. By Route of Administration
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Treatment Type
14.4.2.2. By Route of Administration
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Treatment Type
14.5.2.2. By Route of Administration
14.5.2.3. By Distribution Channel
14.6. UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Treatment Type
14.6.2.2. By Route of Administration
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Treatment Type
14.7.2.2. By Route of Administration
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Treatment Type
14.8.2.2. By Route of Administration
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Treatment Type
14.9.2.2. By Route of Administration
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Treatment Type
14.10.2.2. By Route of Administration
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Treatment Type
14.11.2.2. By Route of Administration
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Treatment Type
14.12.2.2. By Route of Administration
14.12.2.3. By Distribution Channel
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Treatment Type
14.13.2.2. By Route of Administration
14.13.2.3. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Treatment Type
14.14.2.2. By Route of Administration
14.14.2.3. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Treatment Type
14.15.2.2. By Route of Administration
14.15.2.3. By Distribution Channel
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Treatment Type
14.16.2.2. By Route of Administration
14.16.2.3. By Distribution Channel
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Treatment Type
14.17.2.2. By Route of Administration
14.17.2.3. By Distribution Channel
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Treatment Type
14.18.2.2. By Route of Administration
14.18.2.3. By Distribution Channel
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Treatment Type
14.19.2.2. By Route of Administration
14.19.2.3. By Distribution Channel
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Treatment Type
14.20.2.2. By Route of Administration
14.20.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Treatment Type
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. SIGA Technologies Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Chimerix, Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Bavarian Nordic
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Sanofi SA
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Emcure Pharmaceuticals
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Jinan Jinda Pharmaceutical Chemistry Co., Ltd.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Emergent Pharmaceuticals
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Gilead Sciences, Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Hetero
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Piramal Pharma Solutions
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 19: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 21: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 17: Global Market Attractiveness by Treatment Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 37: North America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 77: Europe Market Attractiveness by Treatment Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 82: Asia Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023 to 2033
Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033
Figure 99: Asia Pacific Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 102: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 104: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 109: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 110: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 111: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 115: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 116: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 117: MIDDLE EAST AND AFRICA Market Attractiveness by Treatment Type, 2023 to 2033
Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Route of Administration, 2023 to 2033
Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
